BioSenic S.A. (EBR:BIOS)
Belgium · Delayed Price · Currency is EUR 0.0020
0.00 (0.00%)
May 26, 2026, 10:35 AM CET
BioSenic Revenue
In the year 2025, BioSenic had annual revenue of 24.10B EUR with 266,233.24% growth. BioSenic had revenue of 517.00K in the half year ending December 31, 2025.
Revenue (ttm)
1,000.00
Revenue Growth
-99.96%
P/S Ratio
-0.55
Revenue / Employee
-341.00K
Employees
7
Market Cap
1.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.10B | 24.09B | 266,233.24% |
| Dec 31, 2024 | 9.05M | -2.01M | -18.21% |
| Dec 31, 2023 | 11.06M | 10.80M | 4,058.42% |
| Dec 31, 2022 | 266.00K | -46.00K | -14.74% |
| Dec 31, 2021 | 312.00K | -3.35M | -91.49% |
| Dec 31, 2020 | 3.67M | 1.18M | 47.17% |
| Dec 31, 2019 | 2.49M | -2.59M | -50.95% |
| Dec 31, 2018 | 5.08M | 866.00K | 20.56% |
| Dec 31, 2017 | 4.21M | 206.00K | 5.14% |
| Dec 31, 2016 | 4.01M | 183.00K | 4.79% |
| Dec 31, 2015 | 3.82M | 147.00K | 4.00% |
| Dec 31, 2014 | 3.68M | 283.00K | 8.34% |
| Dec 31, 2013 | 3.39M | 337.00K | 11.02% |
| Dec 31, 2012 | 3.06M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 4.11B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |